Dr Phil Reilly on newborn screening: past, present and future

P.ReillyP.Reilly
W.GreeneW.Greene
BulletArticle
Rare Diseases C-Suite Perspectives Leaders In Conversation Newborn Screening
分享此連結：
複製連結
Dr Phil Reilly on newborn screening: past, present and future

Dr Phil Reilly is a physician, clinical geneticist, biotech entrepreneur, venture capitalist and author with deep experience in rare disease diagnostics, including newborn screening (NBS). In this Q&A with Will Greene, Healthcare Engagement Manager and Project Strongbow Co-Lead at Roche Diagnostics Asia Pacific, we learn more about the history and future of NBS technologies in the United States and around the world.

分享此連結：
複製連結

更多相同主題

Emerging haemophilia therapies highlight a need for quality diagnostics

Newborn screening in Taiwan: Q&A with Dr Yin-Hsiu (Nancy) Chien

建議的主題

定序RED 2020Rare Diseases
接下來讀取
‘Real world evidence’ and clinical labs: a brief introduction
  • Healthcare Transformation, Management, Operations, Population Health Management
‘Real world evidence’ and clinical labs: a brief introduction
‘Chasing the Invisible’ and the future of the clinical lab: Q&A with Dr Thomas Grogan (Part 3)
  • Disease Area, Healthcare Transformation, Histopathology, Leaders In Conversation, Management, Oncology, Operations
‘Chasing the Invisible’ and the future of the clinical lab: Q&A with Dr Thomas Grogan (Part 3)
3 steps to mitigate the impact of interference
  • Clinician Engagement, Coagulation, Disease Area, Management
3 steps to mitigate the impact of interference
A guide to balancing quality, speed and cost
  • Operational Excellence, Operations
A guide to balancing quality, speed and cost
Scroll to Top